Leveraging Community-Academic Partnerships and Social Networks to Disseminate Vaccine-Related Information and Increase Vaccine Uptake Among Black Individuals with Rheumatic Diseases05/10/2022 - 04/30/2025 (Subcontract PI)
Northwestern University NIH NIAMS5R01AR080089-03
ASSET: A Phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis - a double-blind, placebo-controlled, randomized controlled trial [IMI101-344]03/31/2015 - 06/30/2019 (Co-Investigator)
Regents of the University of Michigan Bristol-Myers Squibb
A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis-A Phase I/II Biomarker and Safety Trial04/02/2015 - 04/01/2017 (Co-Investigator)
PI:
Robert A. Lafyatis, MDPRISM Pharma Co Ltd
The Role of Anti-Centromere Antibodies in the Stimulation of Toll-Like Receptor 9 in Systemic Sclerosis07/01/2007 - 06/30/2010 (PI)
Arthritis Foundation
Stimulation of plasmactoid dendritic cells with nucleic-acid containing immune complexes from Scleroderma patients with ant-centromere antibodies07/01/2007 - 06/30/2010 (PI)
American College of Rheumatology Research and Education Foundation
The Role of Anti-Centromere Antibodies in Stimulation of Toll-like receptor 9 in Systemic Sclerosis01/31/2007 - 12/31/2009 (PI)
Scleroderma Federation